miR-135a Inhibits the Invasion of Cancer Cells via Suppression of ERRα

PLoS One. 2016 May 26;11(5):e0156445. doi: 10.1371/journal.pone.0156445. eCollection 2016.

Abstract

MicroRNA-135a (miR-135a) down-modulates parameters of cancer progression and its expression is decreased in metastatic breast cancers (as compared to non-metastatic tumors) as well as in prostate tumors relative to normal tissue. These expression and activity patterns are opposite to those of the Estrogen-Related Receptor α (ERRα), an orphan member of the nuclear receptor family. Indeed high expression of ERRα correlates with poor prognosis in breast and prostate cancers, and the receptor promotes various traits of cancer aggressiveness including cell invasion. Here we show that miR-135a down-regulates the expression of ERRα through specific sequences of its 3'UTR. As a consequence miR-135a also reduces the expression of downstream targets of ERRα. miR-135a also decreases cell invasive potential in an ERRα-dependent manner. Our results suggest that the decreased expression of miR-135a in metastatic tumors leads to elevated ERRα expression, resulting in increased cell invasion capacities.

MeSH terms

  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / pathology
  • Cell Line, Tumor
  • ERRalpha Estrogen-Related Receptor
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Male
  • MicroRNAs / genetics
  • MicroRNAs / metabolism*
  • Neoplasm Invasiveness
  • Neoplasm Metastasis
  • Neoplasm Proteins / biosynthesis*
  • Neoplasm Proteins / genetics
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology
  • RNA, Neoplasm / genetics
  • RNA, Neoplasm / metabolism*
  • Receptors, Estrogen / biosynthesis*
  • Receptors, Estrogen / genetics

Substances

  • MIRN135 microRNA, human
  • MicroRNAs
  • Neoplasm Proteins
  • RNA, Neoplasm
  • Receptors, Estrogen

Grants and funding

This work was funded by Ligue contre le Cancer (comités Puy-de-Dôme https://www.ligue-cancer.net/cd63/journal and Drôme https://www.ligue-cancer.net/cd26/journal) to JS and JMV. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.